Sandoz Q3 2025 slides: Biosimilars drive 6% sales growth, margin guidance raised
PositiveFinancial Markets

Sandoz has reported a 6% sales growth in Q3 2025, driven primarily by its biosimilars portfolio. This growth is significant as it reflects the increasing demand for affordable biologic medicines, which are crucial for patients and healthcare systems alike. Additionally, the company has raised its margin guidance, indicating strong operational performance and confidence in future growth. This news is important as it highlights Sandoz's role in making healthcare more accessible while also ensuring its financial stability.
— Curated by the World Pulse Now AI Editorial System








